New perspectives for TB treatment.

 2011 par Sanofi Pasteur

2011 par Sanofi Pasteur

Pyrazinamide—Old TB Drug Finds New Target

More than 60 years after the discovery of pyrazinamide (PZA), a drug that is a mainstay of combination therapy for tuberculosis (TB), researchers have finally uncovered a mechanism of action that is convincing and novel. Stewart Cole (UPCOL - Chair of Microbial Pathogenesis ) comment (Science Perspective) on resent finding by Shi et al. showing that PZA inhibits trans-translation, a key cellular process for managing damaged proteins and “rescuing” nonfunctioning ribosomes, in Mycobacterium tuberculosis. The finding identifies a potentially promising target for new drugs.

Stewart T. Cole Science Vol. 333 no. 6049 pp. 1583-1584 (2011)


This site uses cookies and analysis tools to improve the usability of the site. More information. |